Ethyl loflazepate

Oral
Short-term management of anxiety

Preexisting CNS depression or coma, respiratory depression, acute pulmonary insufficiency or sleep apnoea; severe hepatic impairment; not indicated for chronic psychosis, phobic or obsessional states; may precipitate suicide or aggressive behaviour, not used alone to treat depression or anxiety associated with depression; glaucoma.

Chronic pulmonary insufficiency; elderly or debilitated patients; muscle weakness, impaired liver or kidney function; drowsiness may affect skilled tasks; monitor cardio-respiratory function when used for deep sedation; patients with personality disorders or organic brain changes; pregnancy, lactation; history of alcohol or drug addiction due to risk of dependence. Respiratory depression and hypotension may occur with parenteral admin.

Drowsiness, sedation, muscle weakness and ataxia; less frequently vertigo, headache, confusion, depression, slurred speech, changes in libido, tremor, visual disturbances, urinary retention, GI disturbances, changes in salivation and amnesia; rarely, jaundice, blood disorders and hypersensitivity reactions; pain and thrombophlebitis; raised liver enzyme values; paradoxical excitation.

Enhanced sedation or respiratory and CV depression with drugs that have CNS depressant properties e.g. antidepressants, antihistamines, antipsychotics, general anesthetics, other hypnotics or sedatives, opioid analgesics and cisapride.
Potentially Fatal: Drugs which alter the hepatic microsomal enzymes.

Alcohol enhances sedation or respiratory and CV depression effects.

Description:
Mechanism of Action: Ethyl loflazepate has general properties similar to diazepam and a long-acting benzodiazepine derivative used in the short-term treatment of anxiety disorders.

Anxiolytics